|
home / press room / news and events / news
 News
September 21, 2007
Intrinsic Bioprobes Inc. receives a Phase II STTR grant (4 R42 DK071290-03) from the National Institute of Diabetes and Digestive and Kidney Diseases at NIH to develop MS BASED APPROACHES FOR DIABETES BIOMARKER DISCOVERY.
August 02, 2007
Intrinsic Bioprobes Inc. receives continued funding on its Phase II SBIR grant (5 R44 AI063651-03) from the National Institute of Allergy and Infectious Diseases at NIH for the Development of MASS SPECTROMETRY ASSAYS FOR BIODEFENSE.
May 22, 2007
Intrinsic Bioprobes Inc. receives continued funding on its Phase II exploratory research grant (5 R33 RR018475-03) from the National Center for Research Resources at NIH for the Development of SPR/MS PROTEIN ARRAY PLATFORM.
November 01, 2006
Intrinsic Bioprobes Inc. moves to a new state-of-the-art facility in Tempe, Arizona. The facility includes research and manufacturing laboratories, and it is located in the ASU Research park, a Science and Technology hub of the Southeast Valley.
September 30, 2006
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant (1 R43 AA016223-01) from the National Institute on Alcohol Abuse and Alcoholism at NIH for the DISCOVERY OF ALCOHOL EXPOSURE BIOMARKERS VIA AFFINITY MASS SPECTROMETRY.
August 15, 2006
Intrinsic Bioprobes Inc. receives a Phase II SBIR grant (2 R44 AI063651-02) from the National Institute of Allergy and Infectious Diseases at NIH for the Development of MASS SPECTROMETRY ASSAYS FOR BIODEFENSE.
June 09, 2006
Intrinsic Bioprobes Inc. receives a Phase II exploratory research grant (4 R33 RR018475-02) from the National Center for Research Resources at NIH for the Development of SPR/MS PROTEIN ARRAY PLATFORM.
June 02, 2006
Intrinsic Bioprobes Inc. receives continued funding on its Phase I STTR grant (5 R42 DK071290-02) from the National Institute of Diabetes and Digestive and Kidney Diseases at NIH to develop MS BASED APPROACHES FOR DIABETES BIOMARKER DISCOVERY
December 13, 2005
Tempe, AZ (USA), December 13, 2005: Tempe-based Intrinsic Bioprobes Inc. was issued its tenth patent, entitled “Mass Spectrometric Immunoassay”. The patent
is the first in a series of applications, and protects the method of using antibody-based affinity isolation
in combination with MALDI-TOF MS to determine the presence of analytes (proteins) in physiological samples.
This targeted proteomics approach has broad application in clinical research and diagnostics.
November 15, 2005
Intrinsic Bioprobes, Inc. receives the Small Company Innovator of the Year award at the third-annual Arizona Governor's
Celebration of Innovation. At the event, Governor Janet Napolitano honored Arizona’s most technologically innovative companies
in three categories: Large Company, Small Company, and Startup. IBI qualified for Small Company Innovator of the Year because
it has been operating for at least two years and generates less than $50 million in annual revenue.
Read more.
September 1, 2005
Intrinsic Bioprobes Inc. receives an exploratory research grant (1 R21 RR018475-01A2) from the National Center for Research Resources at NIH for the Development of SPR/MS PROTEIN ARRAY PLATFORM.
June 1, 2005
Intrinsic Bioprobes Inc. receives a Phase I STTR grant (1 R42 DK071290-01) from the National Institute of Diabetes and Digestive and Kidney Diseases at NIH to develop MS BASED APPROACHES FOR DIABETES BIOMARKER DISCOVERY.
May 3, 2005
Tempe, AZ (USA), May 03, 2005: Tempe-based Intrinsic Bioprobes Inc. received a patent for Bioactive Chip Mass Spectrometry from the U.S. Patent and Trademark Office. The new patent (USPTO # 6,887,713) is the second of a series of patents protecting a lab-on-a-chip approach for the selective targeting and processing of proteins prior to characterization using mass spectrometry.
January 13, 2005
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant (1 R43 AI063651-01) from the National Institute of Allergy and Infectious Diseases at NIH to develop MASS SPECTROMETRY ASSAYS FOR BIODEFENSE AGENTS.
November 15, 2004
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant ( DMI-0441068 ) from the National Science Foundation to develop PROTEOMIC-BASED DETECTION TECHNOLOGY.
October 01, 2004
Intrinsic Bioprobes Inc. unveils its completely redesigned website.
August 31, 2004
IBI issued U.S. patent for integrated high throughput mass spectrometry system for biomolecules
Tempe, AZ (USA), August 31, 2004: Tempe-based Intrinsic Bioprobes Inc. received its seventh patent from the U.S. Patent and Trademark Office. The new patent (USPTO #6,783,672) protects tools and devices used in biomarker discovery. The patent is the first in a series of six related patent applications.
August 06, 2004
Intrinsic Bioprobes Inc. receives continued funding on its Phase II SBIR grant (5 R44 CA099117-03) from the National Cancer Institute at NIH to develop AFFINITY-BASED MASS SPECTROMETRY PROTEIN ASSAYS.
May 27, 2004
Intrinsic Bioprobes Inc. receives continued funding on its Phase II SBIR grant (5 R44 HL072671-03) from the National Heart, Lung and Blood Institute at NIH to develop MASS SPECTROMETRIC IMMUNOASSAYS FOR APOLIPOPROTEINS.
October 15, 2003
Intrinsic Bioprobes Inc. to Develop Specialized Proteomic Informatics System Through Partnership
Tempe, AZ (USA), Oct. 15, 2003: Today, Intrinsic Bioprobes Inc. (IBI) announced its formal relationship with Beavis Informatics Ltd. for the development of a protein analysis and informatics platform to support the full length structural characterization and quantification of human proteins. Through this partnership, Beavis Informatics Ltd. will develop a proprietary informatics system suited for IBI's high-throughput MASSAY system and technologies. The new informatics application responds to the growing demand in clinical proteomics to account for protein diversity found in large study populations.
For the full text of this press release, please click here .
September 02, 2003
Intrinsic Bioprobes Inc. receives a contract from the National Institute of Environmental Health Sciences at NIH (Contract No.N44-ES-35511) to develop MASS SPECTROMETRY BASED HIGH-THROUGHPUT PROTEOMIC APPROACH for detailed protein characterization.
August 26, 2003
Intrinsic Bioprobes Inc. receives a Phase II SBIR grant (4 R44 CA099117-02) from the National Cancer Institute for the Development of AFFINITY-BASED MASS SPECTROMETRY PROTEIN ASSAYS.
July 31, 2003
Intrinsic Bioprobes has won a patent in the United States for its "bioactive chip" technology. US patent No. 6,569,383 covers the use of a single bioactive chip to prepare samples for high-throughput protein analysis, particularly through advantageous techniques of analyte isolation, modification, and concentration.
June 30, 2003
Intrinsic Bioprobes Inc. receives a Phase II SBIR grant (4 R44 HL072671-02) from the National Heart, Lung, and Blood Institute for the Development of MASS SPECTROMETRIC IMMUNOASSAY FOR APOLIPOPROTEINS.
March 24, 2003
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant (1 R44 CA099117-01-01) from the National Cancer Institute at NIH to develop AFFINITY-BASED MASS SPECTROMETRY PROTEIN ASSAYS.
January 13, 2003
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant (1 R44 HL072671-01) from the National Heart, Lung and Blood Institute at NIH to develop MASS SPECTROMETRIC IMMUNOASSAYS FOR APOLIPOPROTEINS.
August 06, 2002
Intrinsic Bioprobes Inc. receives a contract from the National Institute of Environmental Health Sciences at NIH (Contract No. N43-ES-25491) to develop MASS SPECTROMETRY BASED HIGH-THROUGHPUT PROTEOMIC APPROACH for detailed protein characterization.
May 17, 2002
Intrinsic Bioprobes Inc. receives a two-year, Phase II SBIR grant (2 R44 CA82079-03A1) from the National Cancer Institute at NIH to evaluate and validate the use of BIOSENSOR CHIP MASS SPECTROMETRY (BCMST) in important biological applications.
September 21 , 2001
Intrinsic Bioprobes and Bruker Daltonics Announce Strategic Collaboration
Tempe, AZ and Billerica, MA - September 21, 2001 - Intrinsic Bioprobes Inc. (IBI) and Bruker Daltonics Inc. (NASDAQ: BDAL) today announced a strategic collaboration and agreement in the field of MALDI-TOF mass spectrometry. As part of the agreement, Bruker Daltonics' autoflexT MALDI-TOF mass spectrometer will become an integral portion of Intrinsic Bioprobes' MASSAY™ system. MASSAY also incorporates IBI's Bioreactive ProbesT and Mass Spectrometric ImmunoassayT technologies, automation protocols and robotics handling. Financial terms of the agreement were not disclosed.
For the full text of this press release, please click here .
September 01 , 2001
Intrinsic Bioprobes Inc. receives a contract from the National Institute of Diabetes and Digestive and Kidney Diseases at NIH (Contract No. N43DK-1-2470) to develop HIGH-THROUGHPUT MASS SPECTROMETRIC IMMUNOASSAY FOR URINARY PROTEINS.
August 15, 2001
Intrinsic Bioprobes Inc. receives a continued funding on its Phase II SBIR grant (5 R44 GM56603-03) from the National Institute of General Medical Sciences at NIH to develop MASS SPECTROMETRY BASED QUANTITATIVE ASSAYS and devices that enable the routine use of Mass Spectrometric Immunoassays (MSIA™) in biological applications.
June 15 , 2001
Intrinsic Bioprobes Inc. receives a contract from the National Institute on Drug Abuse at NIH (Contract No. N43DA-1-7716) to develop a BIOSENSOR MASS SPECTROMETRY ARRAY for rapid proteome analysis.
June 05 , 2001
Intrinsic Bioprobes Inc. receives a three-year grant from the Arizona Disease Control Research Commision (ID No. 6-066) for PROTEOMIC ANALYSIS OF NICOTINE RECEPTOR STRUCTURE AND COMPOSITION.
September 18, 2000
Intrinsic Bioprobes INC. unveils its new website at www.intrinsicbio.com
September 04, 2000
Intrinsic Bioprobes Inc. receives a continued funding on its Phase II SBIR grant (5 R44 GM56580-03) from the National Institutes of General Medical Sciences at NIH to develop BIOREACTIVE MASS SPECTROMETER PROBES (BRP™), devices for rapid, sensitive and accurate characterization of biomolecules.
July 13, 2000
Intrinsic Bioprobes Inc. receives a Phase II SBIR grant (2 R44 GM56603-02) from the National Institutes of General Medical Sciences at NIH to develop MASS SPECTROMETRY BASED QUANTITATIVE ASSAYS and devices the enable the routine use of Mass Spectrometric Immunoassays (MSIA™) in biological applications.
March 01, 2000
Intrinsic Bioprobes Inc. moves to a new 3,500 square foot, state-of-the-art facility in Tempe, AZ.
September 10, 1999
Intrinsic Bioprobes Inc. receives continued funding for its Phase I SBIR grant (5 R43 CA82079-02) from the National Cancer Institute at NIH to develop BIOSENSOR CHIP MASS SPECTROMETRY (BCMS), an arrayed, chip-based platform intended for use in the rigorous investigation of trace level proteins present in complex biological mixtures.
August 06, 1999
Intrinsic Bioprobes Inc. receives a Phase II SBIR grant (2 R44 GM56580-02) from the National Institutes of General Medical Sciences at NIH to develop BIOREACTIVE MASS SPECTROMETER PROBES (BRP™), devices for rapid, sensitive and accurate characterization of biomolecules.
February 01, 1999
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant (1 R43 GM56603-01A2) from the National Institutes of General Medical Sciences at NIH to develop MASS SPECTROMETRY BASED QUANTITATIVE ASSAYS and devices that enable the routine use of the Mass Spectrometric Immunoassays (MSIA™) in biological applications.
September 28, 1998
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant (1 R43 CA82079-01) from the National Cancer Institute at NIH to develop BIOSENSOR CHIP MASS SPECTROMETRY (BCMS), an arrayed, chip-based platform intended for use in the rigorous investigation of trace level proteins present in complex biological mixtures.
July 01, 1998
Intrinsic Bioprobes Inc. enters into a three-year subcontract with Arizona State University for support of a project titled "Composition of a Unique Receptor for Nicotine", issued under the Arizona Disease Control Research Commission (ADCRC).
February 27, 1998
Intrinsic Bioprobes Inc. receives a Phase I SBIR grant (1 R43 GM56580-01A1) from the National Institute of General Medical Sciences at NIH to develop BIOREACTIVE MASS SPECTROMETER PROBES (BRP™), devices for rapid, sensitive and accurate characterization of biomolecules.
January 1, 1997
IBI licenses BRP technologies from Arizona State University. Tempe-based Intrinsic Bioprobes Inc. announces the licensing of Bioreactive Probe Technologies (BRP) from Arizona State University. The intellectual property protects surface-activated probes that are used in the processing of proteins prior MALDI-TOF MS analysis. Patents include USPTO # 6,004,770, 6,093,541, 6,316,266 and 6,498,039, and Australian Patents # 756020 and 729513. Other US and foreign patents are pending.
|
